- Global Pharma News & Resources

aap Implantate AG / Silver coating technology: Further progress on the way to the targeted market approval - global orthopaedic companies remain keenly interested

DGAP-News: aap Implantate AG / Key word(s): Regulatory Admission/Study

28.03.2019 / 15:34
The issuer is solely responsible for the content of this announcement.

aap Implantate AG ("aap") continued the talks with different global orthopaedic companies in mid-March at the American Academy of Orthopaedic Surgeons ("AAOS") in Las Vegas, USA briefing them especially on the current status regarding its antibacterial silver coating technology. These companies remain keenly interested in aap's innovative silver coating technology.

With a view to the targeted market approval of its silver coating technology aap submitted at the end of 2018 the application to conduct a human clinical study to the Federal Institute for Drugs and Medical Devices ("BfArM") and is now involved in an intensive exchange with the Federal Institute. At the same time, the applications have been submitted to ethics commissions in the meanwhile with a first positive feedback. The next step is the submission of a corresponding application to the US authority.

On the basis of the interaction with the BfArM and the reaffirmation of interest by global orthopaedic companies aap will be further intensifying talks and negotiations with them. Concretely, the Company is discussing in addition to joint product development and approval projects also distribution partnerships as well as licensing deals up to the sale of the technology for specific application areas.


Implantate AG (ISIN DE0005066609) - Prime Standard/Regulated Market - All German stock markets -

About aap Implantate AG
aap Implantate AG is a globally operating medical device company headquartered in Berlin, Germany. The company develops, manufactures and markets trauma products for orthopaedics. The IP protected portfolio includes besides the innovative anatomical plating system LOQTEQ(R) and trauma complementary biomaterials a wide range of cannulated screws as well as standard plates and screws. Furthermore, aap Implantate AG has an innovation pipeline with promising development projects as the antibacterial silver coating technology and magnesium based implants. These technologies address critical problems in surgery that haven't yet been resolved adequately. In German-speaking Europe aap Implantate AG directly sells its products to hospitals, buying syndicates and hospital groups while it uses a broad network of distributors in more than 25 countries at the international level. aap Implantate AG's stock is listed in the Prime Standard segment of Frankfurt Stock Exchange (XETRA: AAQ.DE). For more information, please visit, or download the Company's investor relations app from the Apple's App Store or Google Play.

Forward-looking statement
This release may contain forward-looking statements based on current experience, estimates and projections of the management board and currently available information. They are not guarantees of future performance. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. Many factors could cause the actual results, performance or achievements of aap to be materially different from those that may be expressed or implied by such statements. These factors include those discussed in aap's public reports. Forward-looking statements therefore speak only as of the date they are made. aap does not assume any obligation to update the forward-looking statements contained in this release or to conform them to future events or developments.

aap Implantate AG; Fabian Franke; Investor Relations; Lorenzweg 5; D-12099 Berlin Tel.: +49/30/750 19 - 134; Fax.: +49/30/750 19 - 290;

28.03.2019 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at

Language: English
Company: aap Implantate AG
Lorenzweg 5
12099 Berlin
Phone: +49 (0) 30 75 01 90
Fax: +49 (0) 30 75 01 91 11
ISIN: DE0005066609
WKN: 506660
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange
EQS News ID: 793149

End of News DGAP News Service

Editor Details

Last Updated: 28-Mar-2019